68 related articles for article (PubMed ID: 19755281)
1. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial.
Chevalier B; Serruys PW; Silber S; Garcia E; Suryapranata H; Hauptmann K; Wijns W; Schuler G; Fath-Ordoubadi F; Worthley S; Thuesen L; Meredith I; Bressers M; Nagai H; Paunovic D
EuroIntervention; 2007 Feb; 2(4):426-34. PubMed ID: 19755281
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries.
Kadota K; Muramatsu T; Iwabuchi M; Saito S; Hayashi Y; Ikari Y; Nanto S; Fujii K; Inoue N; Namiki A; Kimura T; Mitsudo K
Catheter Cardiovasc Interv; 2012 Nov; 80(5):789-96. PubMed ID: 21805606
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions.
Lee CW; Park DW; Seung KB; Kim PJ; Park HJ; Kim WJ; Lee JY; Kang SJ; Lee SH; Kim YH; Park SW; Park SJ
Am J Cardiol; 2011 Apr; 107(7):990-4. PubMed ID: 21296317
[TBL] [Abstract][Full Text] [Related]
5. Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects.
Nakamura M; Otsuka Y; Ueda Y; Mitsudo K
Cardiovasc Interv Ther; 2012 Jan; 27(1):24-30. PubMed ID: 24122637
[TBL] [Abstract][Full Text] [Related]
6. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
[TBL] [Abstract][Full Text] [Related]
7. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
[TBL] [Abstract][Full Text] [Related]
9. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating.
Grube E; Hauptmann KE; Buellesfeld L; Lim V; Abizaid A
EuroIntervention; 2005 May; 1(1):53-7. PubMed ID: 19758877
[TBL] [Abstract][Full Text] [Related]
10. First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes.
Ostojic M; Sagic D; Beleslin B; Jung R; Perisic Z; Jagic N; Nedeljkovic M; Mangovski L; Milosavljevic B; Stojkovic S; Orlic D; Antonic Z; Miloradovic V; Topic D; Paunovic D
EuroIntervention; 2008 Mar; 3(5):574-9. PubMed ID: 19608483
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
Leon MB; Mauri L; Popma JJ; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; McLaurin BT; Solomon SL; Douglas JS; Ball MW; Caputo RP; Jain A; Tolleson TR; Reen BM; Kirtane AJ; Fitzgerald PJ; Thompson K; Kandzari DE;
J Am Coll Cardiol; 2010 Feb; 55(6):543-54. PubMed ID: 20152559
[TBL] [Abstract][Full Text] [Related]
12. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
Circulation; 2004 Apr; 109(16):1942-7. PubMed ID: 15078803
[TBL] [Abstract][Full Text] [Related]
13. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial.
Serruys PW; Ruygrok P; Neuzner J; Piek JJ; Seth A; Schofer JJ; Richardt G; Wiemer M; Carrié D; Thuesen L; Boone E; Miquel-Herbert K; Daemen J
EuroIntervention; 2006 Nov; 2(3):286-94. PubMed ID: 19755303
[TBL] [Abstract][Full Text] [Related]
14. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.
Colombo A; Drzewiecki J; Banning A; Grube E; Hauptmann K; Silber S; Dudek D; Fort S; Schiele F; Zmudka K; Guagliumi G; Russell ME;
Circulation; 2003 Aug; 108(7):788-94. PubMed ID: 12900339
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of coronary venous bypass graft lesions treated with a new generation drug-eluting stent with bioabsorbable polymer.
Wessely R; Marzocchi A; Schwacke H; Bertel O; Laanmets P; Perisic Z; Toelg R; Jagic N; Elsässer A; Danzi GB
J Interv Cardiol; 2013 Oct; 26(5):425-33. PubMed ID: 23962106
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
18. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions.
Silber S; Colombo A; Banning AP; Hauptmann K; Drzewiecki J; Grube E; Dudek D; Baim DS
Circulation; 2009 Oct; 120(15):1498-504. PubMed ID: 19786634
[TBL] [Abstract][Full Text] [Related]
19. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial.
Moses JW; Mehran R; Nikolsky E; Lasala JM; Corey W; Albin G; Hirsch C; Leon MB; Russell ME; Ellis SG; Stone GW
J Am Coll Cardiol; 2005 Apr; 45(8):1165-71. PubMed ID: 15837244
[TBL] [Abstract][Full Text] [Related]
20. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
Hermiller JB; Raizner A; Cannon L; Gurbel PA; Kutcher MA; Wong SC; Russell ME; Ellis SG; Mehran R; Stone GW;
J Am Coll Cardiol; 2005 Apr; 45(8):1172-9. PubMed ID: 15837245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
